Log In

Term Description

The Self Evaluation plus Medication Survey is a self-administered instrument which was developed from the questionnaires used in the Collaborative Association Study of Psoriasis (CASP), which is a Genetic Association Information Network (GAIN) genome-wide association study (GWAS). The Self Evaluation plus Medication Survey collects information on individuals with psoriasis and controls, and their family history of psoriasis and other autoimmune diseases. Additionally, for individuals with psoriasis the questionnaire collects information regarding their symptoms and medication use and its effectiveness. The PhenX Skin, Bone, Muscle and Joint Working Group (WG) recommends that investigators provide participants with an informed consent form which allows future contact for physician validation of their diagnosis and to update information on their health status. Immediately following the alcohol and tobacco questions, the Self Evaluation plus Medication Survey asked questions regarding the respondent's weight and height. These questions have been deleted. The Working Group recommends that this information be obtained via the PhenX measures titled Weight and Height, respectively. These measures are located in the PhenX Toolkit, under the Anthropometrics domain.

Reference Information

TypeSourceReference
CitationConsensus measures for Phenotypes and ExposuresThe Self Evaluation plus Medication Survey was provided by the Psoriasis Genetics Laboratory, Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI. Of note, the questions in this survey have been renumbered 1-31.
ArticleConsensus measures for Phenotypes and ExposuresNair, R. P., Stuart, P. E., Nistor, I., Hiremagalore, R., Chia, N. V. C., Jenisch, S., Weichenthal, M., Abeasis, G. R., Lim, H. W., Christophers, E., Voorhees, J. J., & Elder, J. T. (2006). Sequence and haplotype analysis supports HLA-C as the Psoriasis Susceptibility 1 gene. American Journal of Human Genetics, 78, 827-851. PMCID: PMC1474031.
ArticleConsensus measures for Phenotypes and ExposuresNair, R. P., Ruether, A., Stuart, P. E., Jenisch, S., Tejasvi, T., Hiremagalore, R., Schreiber, S., Kabelitz, D., Lim, H. W., Voorhees, J. J., Christophers, E., Elder, J. T., & Weichenthal, M. (2008). Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. Journal of Investigative Dermatology, 128, 1653-1661. PMCID: PMC2739284.
ArticleConsensus measures for Phenotypes and ExposuresNair, R. P., Callis Duffin, K., Helms, C., Ding, J., Stuart, P. E., Goldgar, D., Gudjonsson, J., Li, Y., Tejasvi, T., Feng, B. J., Ruether, A., Schreiber, S., Weichenthal, M., Gladman, D., Rahman, P., Schrodi, S. J., Prahalad, S., Guthery, S. L., Fischer, J., Liao, W., Kwok, P., Menter, A., Lathrop, G. M., Wise, C., Begovich, A. B., Voorhees, J. J., Elder, J. T., Krueger, G. G., Bowcock, A. M., & Abecasis, G. R. (2009). Genome-wide scan of psoriasis reveals association with IL-23 and NF-kB pathways. Nature Genetics, 41(2), 199-204. PMCID: PMC2745122.
ArticleConsensus measures for Phenotypes and Exposuresde Cid, R., Riveira-Munoz, E., Zeeuwen, P. L. J. M., Robarge, J., Liao, W., Dannhauser, E. N., Giardina, E., Stuart, P. E., Nair, R. P., Helms, C., Escarams, G., Ballana, E., Martn-Ezquerra, G., den Heijer, M., Kamsteeg, M., Joosten, I., Eichler, E. E., Lzaro, C., Pujol, R. M., Armengol, L., Abecasis, G., Elder, J. T., Novelli, G., Armour, J. A. L., Kwok, P., Bowcock, A., Schalkwijk, J., & Estivill, X. (2009). Deletion of the late cornified envelope (LCE) 3B and 3C genes as a susceptibility factor for psoriasis. Nature Genetics, 41(2), 211-215. NIHMSID: NIHMS213228.
ArticleConsensus measures for Phenotypes and ExposuresStuart, P. E., Nair, R. P., Hiremagalore, R., Kullavanijaya, P., Kullavanijaya, P., Tejasvi, T., Lim, H. W., Voorhees, J. J., & Elder, J. T. (2010). Comparison of MHC Class I risk haplotypes in Thai and Caucasian psoriatics reveals locus heterogeneity at PSORS1. Tissue Antigens, July 1 [E-pub ahead of print]. NIHMSID: NIHMS215411
ArticleConsensus measures for Phenotypes and ExposuresStuart, P. E., Nair, R. P., Ellinghaus, E., Ding, J., Tejasvi, T., Gudjonsson, J. E., Li, Y., Weidinger, S., Eberlein, B., Gieger, C., Wichmann, H. E., Kunz, M., Ike, R., Mroweitz, U., Lim, H. W., Voorhees, J. J., Abecasis, G. R., Weichenthal, M., Franke, A., Rahman, P., Gladman, D., & Elder, J. T. (in press). Genome-wide association analysis identifies three psoriasis susceptibility loci. Nature Genetics.

Panel Hierarchy

Details for each LOINC in Panel LHC-Forms

LOINCNameR/O/CCardinalityExample UCUM Units
62906-3PhenX - personal and family history of psoriasis protocol 170501
Indent65223-0Age of onseta
Indent63932-8Age at diagnosis?a
Indent66535-6Is the physician who diagnosed you a dermatologist:
Indent67101-6Name of your current dermatologist
Indent66536-4Have you been told by a rheumatologist that you have psoriatic arthritis?
Indent66537-2Have you been diagnosed with Crohn's disease or another inflammatory bowel disorder?
Indent29308-4Diagnosis0..*
Indent63931-0Date of diagnosis?
Indent66538-0Have you been diagnosed with any type of autoimmune disease (lupus, scleroderma, etc.)?
Indent66539-8Do you have any blood relatives affected with psoriasis?
Indent66540-6Do you have any blood relatives with inflammatory bowel disease?
Indent66541-4Do you have any blood relatives with any type of autoimmune disease?
Indent66542-2What color is an average spot of your psoriasis?
Indent66543-0How thick is an average spot of your psoriasis?
Indent66544-8How scaly is an average spot of your psoriasis?
Indent66546-3Has a dermatologist told you that you have pustular psoriasis?
Indent66545-5Do you have nail psoriasis?
Indent67103-2On the drawings below, mark areas of your body affected with psoriasis NOW. Face
Indent8251-1Service comment
Indent67104-0On the drawings below, mark areas of your body affected with psoriasis WHEN IT WAS THE WORST IT HAS EVER BEEN. Face
Indent66547-1Things to smoke [PhenX]
Indent66548-9How many of the following do you smoke per day?
Indent66549-7Topical Medications (creams, lotions, etc.), Systemic medications (oral medications), Biologicals (injected), Phototherapy
Indent66550-5Psoriasis treatment duration [PhenX]
Indent66551-3Psoriasis treatment effectiveness [PhenX]
Indent66552-1Biologicals (injected) Other, please describe
Indent66553-9Other systemics [PhenX]
Indent66554-7Other topicals [PhenX]

LOINC Names Get Info

Fully-Specified Name
PhenX - personal and family history of psoriasis protocol 170501:-:Pt:^Patient:-:PhenX
Long Common Name
PhenX - personal and family history of psoriasis protocol 170501
Short Name
Pers fam hx psoriasis proto

Part Model Get Info

  • Component
    PhenX - personal and family history of psoriasis protocol 170501
    LP112502-2
    • Analyte
      PhenX - personal and family history of psoriasis protocol 170501
      LP112502-2
      • Component Numerator
        PhenX - personal and family history of psoriasis protocol 170501
        LP112502-2
        • Component Numerator Core
          PhenX - personal and family history of psoriasis protocol 170501
          LP112502-2
        • Component Numerator Core Suffix
          NULL
           
      • Component Denominator
        NULL
         
        • Component Denominator Core
          NULL
           
        • Component Denominator Core Suffix
          NULL
           
    • Challenge
      NULL
       
    • Adjustment
      NULL
       
    • Count
      NULL
       
  • Property
    -
    LP6769-6
  • Time
    Pt
    LP6960-1
  • System
    ^Patient
    LP310005-6
    • System Core
      NULL
       
    • Super System
      Patient
      LP6985-8
  • Scale
    -
    LP7747-1
  • Method
    PhenX
    LP95333-8

Survey Question

PX170501

Basic Attributes

Class
PANEL.PHENX
Type
Clinical
First Released
Version 2.36
Last Updated
Version 2.81 (MIN)
Change Reason
Release 2.81: Status: Changing PhenX Concept from Status = Trial to Active; Previous Releases: Updated the PhenX ID from "PhenX.<ID>" to "PX<ID>" in Survey Question Source field to align with the variable identifier used in the PhenX Toolkit.; Added the PhenX protocol ID to the Component to clearly define the protocol version for which this panel is based upon.
Panel Type
Panel

Member of these Panels

LOINCLong Common Name
62896-6PhenX domain - Skin, bone, muscle and joint

Language Variants Get Info

TagLanguageTranslation
el-GRGreek (Greece)PhenX - προσωπικό και οικογενειακό ιστορικό ψωρίασης πρωτόκολλο 170501:-:Pt:^Ασθενής:-:PhenX
Synonyms: - PANEL.PHENX PHENX PhenX - προσωπικό και οικογενειακό ιστορικό ψωρίασης πρωτόκολλο 170501 Pt Ασθενής
es-MXSpanish (Mexico)PhenX - protocolo 170501 de antecedentes personales y familiares de psoriasis:-:Punto temporal:^ Paciente:-:PhenX
it-ITItalian (Italy)PhenX - anamnesi personale e familiare di psoriasi, protocollo:-:Pt:^Paziente:-:PhenX
Synonyms: Panel PhenX paziente PhenX Punto nel tempo (episodio)
ru-RURussian (Russian Federation)PhenX - личная и семейная история псориаз протокол:-:ТчкВрм:^Пациент:-:PhenX
Synonyms: Точка во времени;Момент
zh-CNChinese (China)PhenX - 银屑病个人与家族史方案 170501:-:时间点:^患者:-:PhenX
Synonyms: Consensus measures for Phenotypes and eXposures;PhenX;暴露;接触;表型与暴露共识指标;表现型与暴露共识指标;表型与暴露公认指标 Consensus measures for Phenotypes and eXposures;表型与暴露共识指标;表现型与暴露共识指标;表型与暴露公认指标 医嘱套餐 医嘱套餐类 医嘱套餐组 医嘱组 医嘱组.PhenX;组套（组合、医嘱组、套餐、套餐医嘱、医嘱套餐、组合申请、组合项目）.PhenX;Consensus measures for Phenotypes and eXposures;PhenX;表型与暴露共识指标;表现型与暴露共识指标;表型与暴露公认指标;PhenX 医嘱组 医嘱组合 医嘱组合类 医嘱组套 医嘱组套类 医嘱组类 医疗服务对象;客户;病人;病患;病号;超系统 - 病人 多重;多重型;多重标尺类型;多重精度类型 套餐 套餐医嘱 套餐医嘱组 套餐医嘱组类 实验室医嘱套餐 实验室医嘱套餐类 实验室医嘱组 实验室医嘱组合类 实验室医嘱组套 实验室医嘱组套类 实验室套餐医嘱组 实验室套餐医嘱组类 实验室检验项目医嘱组合类 实验室检验项目组合类 时刻;随机;随意;瞬间 检验医嘱组合类 检验项目医嘱组合类 检验项目组合类 组 组合 组合医嘱 组合类 组套

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=62906-3
Questionnaire definition
https://fhir.loinc.org/Questionnaire/?url=http://loinc.org/q/62906-3